Please select CHADSVASC and HASBLED risk factors, EHRA score and click copy to
clipboard to copy and paste in your electronic files
Chadsvasc risk factors [click on present risk factors]
|
RISK FACTORS
|
SCORE
|
|
Congestive heart failure
The presence of signs and symptoms of either right or left ventricular failure or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction. E.g. LVEF < 40%.
|
1
|
|
Hypertension
A resting blood pressure >140mmHg systolic and/or >90mmHg diastolic on at least 2 occasions or current antihypertensive pharmacologic treatment.
|
1
|
|
Age ≥ 75
Age>75
|
2
|
|
Age 65-74
Age 65-74
|
1
|
|
Diabetes mellitus
Fasting plasma glucose level ≥7.0 mmol/L (126 mg/dL) or treatment with oral hypoglycaemic agent and/or insulin
|
1
|
|
Stroke/TIA/thrombo-embolism
|
2
|
|
Vascular disease
Prior myocardial infarction, angina pectoris, percutaneous coronary intervention or coronary artery bypass surgery.The presence of any the following: intermittent claudication, previous surgery or percutaneous intervention on the abdominal aorta or the lower extremity vessels, abdominal or thoracic surgery, aterial and venous thrombosis.
|
1
|
|
Sex Female
Sex Female
|
1
|
|
Your score
|
0
|
CHADSVASC clinical risk estimation. Adapted from Lip et al. See Van den Ham et
al. below for actual risks in a larger population.
|
CHA2DS2VASc
SCORE |
PATIENTS (n=7329)
|
ADJUSTED STROKE RATE (% year)
|
|
0
|
1
|
0%
|
|
1
|
422
|
1.3%
|
|
2
|
1230
|
2.2%
|
|
3
|
1730
|
3.2%
|
|
4
|
1718
|
4.0%
|
|
5
|
1159
|
6.7%
|
|
6
|
679
|
9.8%
|
|
7
|
294
|
9.6%
|
|
8
|
82
|
6.7%
|
|
9
|
14
|
15.2%
|
HASBLED clinical characteristic [click on present risk factors]
|
CLINICAL CHARACTERISTIC
|
POINTS
AWARDED |
|
Hypertension
Uncontrolled, > 160 mmHg systolic
|
1
|
|
Abnormal liver function
Abnormal liver function
|
1
|
|
Abnormal renal function
Abnormal renal function
|
1
|
|
Stroke
Previous history, particularly lacunar
|
1
|
|
Bleeding
Bleeding history or predisposition (anemia)
|
1
|
|
Labile INRs
Therapeutic time in range < 60%
|
1
|
|
Elderly (Age >65)
Age > 65
|
1
|
|
Drugs
Antiplatelet agents or NSAIDs
|
1
|
|
Alcohol
Alcohol use ≥ 8u / week
|
1
|
|
Your score
|
0
|
HASBLED clinical risk estimation. Adapted from Pisters et al.
|
HAS BLED
SCORE |
NUMBER OF
PATIENTS |
NUMBER OF
BLEEDING |
BLEEDS PER
100 PATIENT YEARS |
|
0
|
798
|
9
|
1.13
|
|
1
|
1286
|
13
|
1.02
|
|
2
|
744
|
14
|
1.88
|
|
3
|
187
|
7
|
3.74
|
|
4
|
46
|
4
|
8.70
|
|
5
|
8
|
1
|
12.50
|
|
6
|
2
|
0
|
0
|
|
7
|
---
|
---
|
---
|
|
8
|
---
|
---
|
---
|
|
9
|
---
|
---
|
---
|
|
Total
|
798
|
9
|
1.13
|
Classificaton of AF-related symptoms (EHRA score)
|
EHRA I
|
No symptoms
|
|
EHRA II
|
Mild symptoms; normal daily activity not affected
|
|
EHRA III
|
Severe symptoms; normal daily activity affected
|
|
EHRA IV
|
Disabling symptoms; normal daily activity discontinued
|
CHA2DS2-VASc=not filled
in; HASBLED=not filled in
copy to clipboard
copied to clipboard
cha2ds2-vasc=not filled in; hasbled=not filled in
copy to clipboard
copied to clipboard
cha2ds2-vasc=not filled in; hasbled=not filled in
copy to clipboard
copied to clipboard
| Haemorrhagic risk | Stroke risk | Clinical setting | Recommendations according to EHRA / ESC / EAPCI 2014 consensus document |
|---|---|---|---|
| Low or moderate (HAS-BLED 0-2) |
Moderate (CHA2DS2-VASC = 1 in males) |
Stable CAD |
At least 4 weeks (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day
+ clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
| High (CHA2DS2-VASC ≥2) |
Stable CAD |
At least 4 weeks (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day
+ clopidogrel 75 mg/day<
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100
mg/day)
Lifelong: OAC
|
|
| Moderate (CHA2DS2-VASC = 1 in males) |
ACS |
6 months: triple therapy of OAC + aspirin 75-100 mg/day +
clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| High (CHA2DS2-VASC ≥2) |
ACS |
6 months: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively,
aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| High (HAS-BLED ≥3) |
Moderate (CHA2DS2-VASC = 1 in males) |
Stable CAD |
Up to 12th month: OAC and clopidogrel 75 mg/day
Lifelong: OAC
|
| High (CHA2DS2-VASC ≥2) |
Stable CAD |
4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| Moderate (CHA2DS2-VASC = 1 in males) |
ACS |
4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75
mg/dayd
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| High (CHA2DS2-VASC ≥2) |
ACS |
4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75
mg/dayd
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|